Clinical Trials Directory

Trials / Conditions / Intestinal Adenocarcinoma of the Stomach

Intestinal Adenocarcinoma of the Stomach

13 registered clinical trials studyying Intestinal Adenocarcinoma of the Stomach.

StatusTrialSponsorPhase
WithdrawnC-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced
NCT02344810
Eastern Cooperative Oncology GroupPhase 1 / Phase 2
Completed64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
NCT01939275
City of Hope Medical CenterN/A
CompletedPilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esop
NCT01612546
City of Hope Medical CenterPhase 2
CompletedGenotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointest
NCT01643499
University of ChicagoPhase 1
CompletedEverolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
NCT01231399
City of Hope Medical CenterPhase 1 / Phase 2
CompletedBevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal
NCT01212822
Fox Chase Cancer CenterPhase 2
CompletedIrinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophag
NCT00991952
National Cancer Institute (NCI)Phase 2
CompletedS0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
NCT00103324
National Cancer Institute (NCI)Phase 2
CompletedIrinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroe
NCT00084604
National Cancer Institute (NCI)Phase 2
CompletedPhase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carc
NCT00084617
National Cancer Institute (NCI)Phase 2
TerminatedA Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
NCT00064259
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedBortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Sto
NCT00061932
National Cancer Institute (NCI)Phase 2
CompletedVaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
NCT00028496
National Cancer Institute (NCI)Phase 1